Quick Answer
Immix Biopharma, Inc. reported Total Assets of $104.84 million for the year ending 2025.
- Immix Biopharma, Inc. showed an increase of +356.9% in Total Assets from 2024 to 2025.
- This data is from Immix Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $20.02 million | Q2 2022: $19.09 million | Q3 2022: $17.40 million | Q1 2023: $13.21 million | Q2 2023: $15.57 million | Q3 2023: $22.47 million | Q1 2024: $34.35 million | Q2 2024: $28.84 million | Q3 2024: $25.14 million | Q1 2025: $19.89 million | Q2 2025: $15.64 million | Q3 2025: $20.08 million.
- Over the full 6 years of available data (2020 to 2025), Immix Biopharma, Inc.'s Total Assets has grown by 19,329.4%.
- Historical annual values: Fiscal year 2025: $104.84 million | Fiscal year 2024: $22.95 million | Fiscal year 2023: $19.93 million | Fiscal year 2022: $14.91 million | Fiscal year 2021: $18.19 million | Fiscal year 2020: $539.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: